19 related results for rivaroxaban


NOACs confer lower bleeding risk than VKA in low-risk AF patients

Literature 21-6-2017 • Lip GYH et al., JAMA Cardiol. 2017
In AF patients with a single non-gender-related stroke risk factor, the risk of any bleeding was lower for apixaban and dabigatran compared with warfarin, while no difference in stroke prevention was seen.

FORTA classifies all DOACs and warfarin as beneficial for older AF patients

Literature 17-5-2017 • Wehling M, et al, Drugs & Aging 2017
Based on FORTA classification, all DOACs and warfarin were classified as beneficial or very beneficial for older AF patients, while there was lack of evidence for other vitamin K antagonists.

Doubled risk of acute MI in real world AF patients receiving DOACs or aspirin vs. VKA

Literature 11-4-2017 • Stolk LM et al., Br J Clin P harmacol 2017
Analysis of new users of rivaroxaban or dabigatran, aspirin and VKAs in CPRD reveals a two-fold increased risk of AMI in current users of DOAC or aspirin, as compared with VKA.

Undercoagulation was common in AF patients who suffered from stroke and impacts outcome

Literature 5-4-2017 • Xian Y et L., JAMA. 2017
In a contemporary registry, 84% of patients with a history of AF received no or subtherapeutic anticoagulation, which affected severity of stroke and in-hospital mortality.

Gastrointestinal safety profiles differ among direct oral anticoagulants

Literature 28-3-2017 • Abraham NS, et al, Gastroenterology 2017
In a large population-based cohort of AF patients on DOACs, apixaban had most favourable gastrointestinal safety profile among all age groups, and rivaroxaban the least favourable. 

No role for aspirin in long-term prevention of recurrent VTE

News 21-3-2017
ACC 2017 In the EINSTEIN CHOICE study, rivaroxaban, at both 20 mg and 10 mg doses, was more effective than aspirin for the prevention of recurrent venous thromboembolism after 6 to 12 months of therapy.

Reduced doses NOAC show similar efficacy and bleeding risk but possibly higher mortality risk

Literature 20-2-2017 • Nielsen PB et al., BMJ. 2017
Real-world data show lower dose NOACs associated with similar risk of thromboembolic events and similar or lower rates of bleeding as compared with warfarin in AF, but mortality risk seems higher with NOACs.

Lower risk of liver injury hospitalisation with DOACs as compared to warfarin

Literature 10-1-2017 • Alonso A et al., Heart. 2017
Dabigatran, rivaroxaban and apixaban users were less often associated with liver injury hospitalisation compared to warfarin and several variables could predict this.

DOACs also beneficial for elderly AF and VTE patients

Literature 11-10-2016 • Sadlon AH, Swiss Med Wkly, 2016
Rivaroxaban, apixaban, dabigatran and edoxaban were superior to VKAs in a meta-analysis of 8 studies comprising elderly patients with atrial fibrillation or venous thromboembolism.

Real-world safety data show differences between anticoagulants in AF patients

Literature 23-8-2016 • Lip GYH et al., Thromb Haemost 2016
In a real-world observational study using propensity score matched cohorts, apixaban initiation was associated with significantly lower risk of major bleeding compared to warfarin and rivaroxaban.

EHRA practical guide for non-vitamin K antagonist anticoagulants in non-valvular AF patients updated

News 15-6-2016
The European Heart Rhythm Association (EHRA) published a rewritten, updated version of the previously published (2013) guidelines for NOACs in non-valvular AF patients.

Direct oral anticoagulants result in lower risk of dementia in atrial fibrillation patients

Literature 9-6-2016 • Jacobs V, et al. Am J Cardiol. 2016
Treatment with direct oral anticoagulants was associated with a lower risk of cerebral ischemic events and new-onset dementia, in a retrospective analysis of 5,254 patients with atrial fibrillation.

Adherence to oral anticoagulation affects outcomes in AF patients at high stroke risk

Literature 29-2-2016 • Yao et al., J Am Heart Assoc. 2016
In patients with atrial fibrillation, adherence to oral anticoagulation for stroke prevention was modestly improved by the use of NOACs, which impacts mainly the outcomes of high-risk patients.

Polypharmacy in patients with AF can increase bleeding risk

Literature 2-2-2016 • Piccini JP et al., Circulation 2016
The risk of major bleeding with rivaroxaban compared with warfarin was reduced in patients in ROCKET-AF taking fewer than 5 medications, but not in patients taking 5 or more medications, whereas the risk of stroke was not influenced by multiple medications.

Incidence of major bleedings with rivaroxaban in real world similar to trial setting

Literature 28-1-2015 • Tamayo S et al., Clin Cardiol 2015
The incidence of major bleeding in patients with NVAF taking rivaroxaban in standard clinical practice was similar to randomised trials. Most bleedings were of gastrointestinal or intracranial origin and fatal bleedings were rare.

Rivaroxaban also effective at reducing stroke in AF patients over 75 years

Literature 16-6-2014 • Halperin JL et al., Circulation 2014
Factor Xa inhibition is as effective as adjusted-dose warfarin to anticoagulate patients of over 75 years old with nonvalvular AF, tor the prevention of stroke and systemic embolism.

Time in therapeutic range does not affect treatment benefits of rivaroxaban vs. warfarin

Literature 28-4-2014 • Piccini JP, J Am Heart Assoc. 2014
A wide range of centre TTRs were seen in ROCKET-AF, but the relative efficacy of rivaroxaban over warfarin did not vary with cTTR, for stroke prevention in atrial fibrillation.

Higher bleeding risk even with brief use of NSAID or aspirin, when on anticoagulation

Literature 23-4-2014 • Davidson BL et al., JAMA Intern Med. 2014
A clinically important increase in bleedings was observed in patients treated for VTE, who are simultaneously using anticoagulation and NSAIDs or aspirin.

Favourable risk/benefit ratio of NOACs over warfarin in meta-analysis of large trials

Literature 9-12-2013 • Ruff et al., The Lancet 2013
Combined data from RE-LY, ROCKET-AF, ARISTOTLE and ENGAGE AF-TIMI 48 showed that NOACs safely reduce stroke and systemic embolism in comparison with warfarin, in atrial fibrillation.

Upcoming meetings

EPCCS Council Meeting December 6-7, 2017, Stratford Upon Avon, United Kingdom
10th EPCCS Annual CV Summit for Primary care March 15-16, 2018, Malaga, Spain
All upcoming meetings...

Meeting reports & resources

EPCCS 2017 Report of the Cardiovascular Summit held in Dublin, Ireland
EPCCS Guidance Documents Evidence- and meeting-based guidance for primary care
EPCCS 2015 Report of 8th Annual EPCCS meeting held in Prague.
EPCCS 2014 Report of 7th Annual EPCCS meeting held in Brussels.
All meeting reports...